NAVB---I wonder if some of recent gains besides tracking the general biotech sector are related to a recent,formal complaint to SEC about hedge fund manager Martin Shkreli who is attempting to gain podium time at several upcoming drug approval meetings with FDA despite having no scientific background and being on record as having a short position in the various co's.
I am attempting to contact the FDA currently about his recent tweets to try and give comments at Arena's upcoming Advisory Committee in Q2 (no date set).
News 
Market Data 
Discover 
AI
